iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted immunotherapies. This strategic acquisition significantly enhances iOncologi’s capabilities in developing cutting-edge immunotherapies for solid tumors.
As part of the transaction, iOncologi, Inc. and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99% of TargImmune’s shares, warrants, and options. Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc. This structure ensures the seamless continuation of TargImmune’s research into novel tumor-targeted RNA therapies while benefiting from iOncologi’s expanded resources and strategic vision.
Health Technology Insights: HealthStream reduces office space with hybrid culture, subleases
“This acquisition represents a pivotal moment for iOncologi as we continue to push the boundaries of immunotherapy for solid tumors,” said Dr. Edgardo Rodriguez-Lebron, iOncologi’s recently appointed CEO. “TargImmune’s pioneering approaches perfectly align with our mission to develop transformative cancer therapies. By integrating two incredibly talented and highly experienced drug development teams, we are well-positioned to accelerate innovation and bring novel treatments to patients with limited therapeutic options.”
The acquisition aligns with iOncologi’s broader strategy to expand its therapeutic pipeline, leverage next-generation RNA-based immunotherapies, and drive innovation in oncology.
Health Technology Insights: Nimblemind.ai raises $2.5Million to unlock AI-ready clinical data
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
